{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:47:51Z","timestamp":1793717271587,"version":"4.6.1"},"reference-count":13,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is not a recognised complication. Recent case reports have emerged describing drug-induced liver injury associated with tirzepatide. We present a case of a woman aged in her 20s who developed acute hepatocellular injury within four\u2009weeks of commencing tirzepatide. Extensive investigations did not reveal an alternative cause of liver injury. Following the cessation of tirzepatide, the patient demonstrated clinical and biochemical recovery over the following four\u2009weeks.<\/jats:p>","DOI":"10.1136\/bcr-2025-269172","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:10:15Z","timestamp":1775229015000},"page":"e269172","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Drug-induced liver injury secondary to tirzepatide"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-4592","authenticated-orcid":false,"given":"Chester Yixuan","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia"},{"name":"Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deloshaan","family":"Subhaharan","sequence":"additional","affiliation":[{"name":"Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia"},{"name":"Bond University, City of Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mikhail-Gouda","sequence":"additional","affiliation":[{"name":"Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia"},{"name":"Bond University, City of Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Haig","sequence":"additional","affiliation":[{"name":"Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia"},{"name":"Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026062608152125000_19.4.e269172.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"2026062608152125000_19.4.e269172.2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"The Lancet"},{"key":"2026062608152125000_19.4.e269172.3","doi-asserted-by":"crossref","unstructured":"Mishra R , Raj R , Elshimy G , et al . Adverse Events Related to Tirzepatide. Journal of the Endocrine Society 2023;7. doi:10.1210\/jendso\/bvad016","DOI":"10.1210\/jendso\/bvad016"},{"key":"2026062608152125000_19.4.e269172.4","unstructured":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases . LiverTox: clinical and research information on drug-induced liver injury [internet]. National Centre for Biotechnology Information; 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK581694\/"},{"key":"2026062608152125000_19.4.e269172.5","doi-asserted-by":"crossref","unstructured":"Ahmed RT , Almatrooshi CA , AlShehhi SJ , et al . A Rare Case of Tirzepatide-Induced Hepatitis: Causality Assessment With the RUCAM Criteria. AIM Clinical Cases 2025;4. doi:10.7326\/aimcc.2024.0923","DOI":"10.7326\/aimcc.2024.0923"},{"key":"2026062608152125000_19.4.e269172.6","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.cgh.2024.06.025","article-title":"First Report of Tirzepatide Hepatotoxicity with Jaundice","volume":"22","author":"Fontana","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062608152125000_19.4.e269172.7","first-page":"949","article-title":"A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors","volume":"12","author":"Jiang","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"2026062608152125000_19.4.e269172.8","article-title":"Tirzepatide-Related Acute Liver Injury","volume":"11","author":"Abdullah","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"2026062608152125000_19.4.e269172.9","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001661","article-title":"Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect","volume":"12","author":"Phox","year":"2025","journal-title":"ACG Case Rep J"},{"key":"2026062608152125000_19.4.e269172.10","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001484","article-title":"A Rare Case of Tirzepatide-Induced Hepatotoxicity","volume":"11","author":"Sohal","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026062608152125000_19.4.e269172.11","first-page":"73","article-title":"Drug-induced Liver Injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"2026062608152125000_19.4.e269172.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1750"},{"key":"2026062608152125000_19.4.e269172.13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future","volume":"10","author":"Danan","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:21:15Z","timestamp":1782487275000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,3]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bcr-2025-269172"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269172","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}